{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T03:29:46Z","timestamp":1768706986821,"version":"3.49.0"},"reference-count":19,"publisher":"Japanese Society of Internal Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,1,15]]},"DOI":"10.2169\/internalmedicine.5535-25","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T18:07:50Z","timestamp":1750874870000},"page":"318-321","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Tucidinostat Pre-emptive Therapy for Peripheral T-cell Lymphoma after Allogeneic Stem Cell Transplantation"],"prefix":"10.2169","volume":"65","author":[{"given":"Kohei","family":"Takada","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Tachi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuto","family":"Shonai","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Kawasaki","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiro","family":"Sone","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiraku","family":"Ogata","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichiro","family":"Kato","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiko","family":"Kimura","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Broccoli A, Zinzani PL. Peripheral T-cell lymphomas. Hematol Oncol 41 (suppl 1): 82-87, 2023.","DOI":"10.1002\/hon.3142"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Chihara D, Fanale MA, Miranda RN, et al. The survival outcome of patients with relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol 176: 750-758, 2017.","DOI":"10.1111\/bjh.14477"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Chen AI, McMillan A, Negrin RS, Horning SJ, Laport GG. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant 14: 741-747, 2008.","DOI":"10.1016\/j.bbmt.2008.04.004"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Lansigan F, Seropian S, Cooper D, Foss F. A retrospective comparison of autologous vs. allogeneic transplantation for peripheral T-cell lymphoma: a single institution experience. Blood 112: 4392, 2008.","DOI":"10.1182\/blood.V112.11.4392.4392"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Dodero A, Spina F, Narni F, et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed\/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 26: 520-526, 2012.","DOI":"10.1038\/leu.2011.240"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Corradini P, Dodero A, Zallio F, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin&apos;s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22: 2172-2176, 2004.","DOI":"10.1200\/JCO.2004.12.050"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Mamez AC, Dupont A, Blaise D, et al. Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC). J Hematol Oncol 13: 56, 2020.","DOI":"10.1186\/s13045-020-00892-4"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Glaser KB. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 74: 659-671, 2007.","DOI":"10.1016\/j.bcp.2007.04.007"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Rai S, Kim WS, Ando K, et al. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results. Haematologica 108: 811-821, 2023.","DOI":"10.3324\/haematol.2022.280996"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Zhu Y, Yu W, Jin J, et al. Tucidinostat maintenance after achieving objective response to first-line therapy in peripheral T-cell lymphoma: a single-center retrospective case-control study. Blood 140 (suppl 1): 3694-3695, 2022.","DOI":"10.1182\/blood-2022-163186"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Wang Z, Qin G, Zhao TC. HDAC4: mechanism of regulation and biological functions. Epigenomics 6: 139-150, 2014.","DOI":"10.2217\/epi.13.73"},{"key":"12","unstructured":"12. Pan LN, Lu J, Huang B. HDAC inhibitors: a potential new category of anti-tumor agents. Cell Mol Immunol 4: 337-343, 2007."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Dahiya S, Beier UH, Wang L, et al. HDAC10 deletion promotes Foxp3<sup>+<\/sup> T-regulatory cell function. Sci Rep 10: 424, 2020.","DOI":"10.1038\/s41598-019-57294-x"},{"key":"14","doi-asserted-by":"crossref","first-page":"e1341031","DOI":"10.1080\/2162402X.2017.1341031","volume":"6","author":"Y Chu","year":"2017","unstructured":"14. Chu Y, Yahr A, Huang B, Ayello J, Barth M, Cairo MS. Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma <i>in vitro<\/i> and in immunodeficient mice. OncoImmunology 6: e1341031, 2017.","journal-title":"OncoImmunology","ISSN":"https:\/\/id.crossref.org\/issn\/2162-4011","issn-type":"print"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Mamez AC, Souchet L, Roos-Weil D, et al. Graft-versus-T-cell lymphoma effect: a sustained CR after tapering immunosuppressive drugs in a patient with angioimmunoblastic T-cell lymphoma in relapse after allogeneic transplantation. Bone Marrow Transplant 50: 304-306, 2015.","DOI":"10.1038\/bmt.2014.243"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Hosing C, Braunstein Z, McLaughlin E, et al. Post-allograft romidepsin maintenance mitigates relapse risk and stimulates the graft-versus-malignancy effect through enhanced NK-cell cytotoxicity in patients with T-Cell malignancies: final results of a phase I\/II trial. Blood 142 (suppl 1): 184, 2023.","DOI":"10.1182\/blood-2023-190213"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Rashidi A, Weisdorf DJ, Bejanyan N. Treatment of relapsed\/refractory acute myeloid leukaemia in adults. Br J Haematol 181: 27-37, 2018.","DOI":"10.1111\/bjh.15077"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Hourigan CS, Karp JE. Minimal residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol 10: 460-471, 2013.","DOI":"10.1038\/nrclinonc.2013.100"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Mamez AC, L\u00e9vy V, Chevallier P, et al. Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC). Bone Marrow Transplant 51: 358-364, 2016.","DOI":"10.1038\/bmt.2015.280"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/2\/65_5535-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T03:33:20Z","timestamp":1768620800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/2\/65_5535-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5535-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"article-number":"5535-25"}}